Dive Brief: CMS has proposed giving companies including Boston Scientific and Stryker an extra year of new technology add-on payments (NTAP) for their medical devices under the agency's Fiscal 2022 Inpatient Prospective Payment System rule. Typically, CMS gives add-on payments to hospitals for two to three years after the introduction of new technologies that meet certain criteria. The agency has extended the payments for 14 products beyond the typical timeframe in light of the COVID-19 pandemic. The extension covers Boston Scientific's Eluvia drug-eluting stent, Cook Medical's Hemospray, Stryker's SpineJack system and other medical devices and therapeutics. Dive Insight: CMS sets payment rates for inpatient stays annually, accounting for changes in the cost of products and services used to treat patients with various conditions. The annual updates use the most recent Medicare claims and cost report data to determine cost changes. However, as the information has a lag of two to three years, the approach fails to capture the impact of new technologies.